Hair Loss in Women: Causes, Treatments & What Actually Works

Hair loss affects an estimated 40% of women by age 50 — yet it remains one of the most underdiagnosed and undertreated conditions in women's health. Unlike the more socially visible pattern baldness in men, female hair loss often presents subtly: a widening part, less volume in a ponytail, or gradual thinning at the crown. Getting to the root cause is the first step toward effective treatment.

Types of Hair Loss in Women: Not All Shedding Is the Same

Understanding which type of hair loss you're experiencing is critical because each type has a different cause — and a different treatment approach.

Female Pattern Hair Loss (FPHL / Androgenetic Alopecia) is the most common type, affecting roughly 30 million women in the United States. It's driven by genetic sensitivity to androgens (male hormones like DHT), which cause hair follicles to miniaturize over time. Unlike male pattern baldness, FPHL typically presents as diffuse thinning at the crown and widening part rather than a receding hairline. It progresses gradually and does not cause complete baldness.

Telogen Effluvium (TE) is a temporary, diffuse shedding triggered by a physiological or emotional stressor. The hair cycle is disrupted, pushing a large percentage of follicles into the resting (telogen) phase simultaneously. Shedding typically begins 2–4 months after the triggering event and can last 6–12 months before resolving on its own. Common triggers include illness, surgery, significant weight loss, crash dieting, and extreme stress.

Alopecia Areata is an autoimmune condition in which the immune system attacks hair follicles, causing patchy, unpredictable hair loss. It can affect any area of the scalp or body and ranges from small coin-sized patches to total scalp hair loss (alopecia totalis). Treatment often involves immunosuppressive approaches.

Traction Alopecia results from repeated tension on the hair follicle from tight hairstyles (braids, ponytails, extensions). Over time, this mechanical stress damages follicles — and if left untreated, hair loss can become permanent.

Hormonal Causes: Estrogen, Androgens, and the Thyroid

Hormones are among the most frequent drivers of female hair loss, and imbalances are often correctable with treatment.

• Androgens (DHT sensitivity): Even women with "normal" androgen levels can experience FPHL if their follicles are genetically sensitive to DHT. Elevated androgens — from PCOS, adrenal disorders, or tumors — can accelerate this process significantly.
• Estrogen decline: Estrogen prolongs the hair growth (anagen) phase. As estrogen levels drop during perimenopause and menopause, more follicles shift to the shedding phase — contributing to the thinning many women notice in their 40s and 50s.
• Thyroid dysfunction: Both hypothyroidism and hyperthyroidism can cause diffuse hair shedding. Thyroid-related hair loss often resolves once thyroid levels are normalized through medication.
• Iron deficiency: Ferritin levels below 30–40 ng/mL are associated with hair shedding, even without anemia. This is one of the most commonly overlooked causes of TE in women of reproductive age.

A key workup for women with new or worsening hair loss should include: TSH, free T4, ferritin, CBC, DHEA-S, total testosterone, and fasting glucose — in addition to a clinical exam of the scalp and hair pattern.

Postpartum Hair Loss: When to Worry

Postpartum hair loss — or postpartum telogen effluvium — is extremely common, affecting up to 50% of women after delivery. During pregnancy, elevated estrogen levels prolong the anagen (growth) phase, resulting in thicker, fuller hair. After delivery, as estrogen levels drop rapidly, many follicles simultaneously enter the telogen phase, and shedding begins around months 2–5 postpartum.

The good news: postpartum TE is almost always self-limiting. Hair typically regrows fully within 6–12 months without treatment. However, if shedding is severe, prolonged beyond 12 months, or associated with a widening part (suggesting FPHL rather than TE), medical evaluation is warranted. Nutritional support — particularly adequate iron, protein, and B vitamins — can support recovery and regrowth speed.

PCOS and Hair Loss: A Common Connection

Polycystic ovary syndrome (PCOS) affects 8–13% of reproductive-age women and is one of the leading hormonal causes of hair loss in women under 40. PCOS is characterized by elevated androgens, which can drive both hirsutism (excess facial/body hair) and FPHL simultaneously. This paradoxical combination — unwanted hair growth in some areas while losing scalp hair — is a hallmark of androgenic excess.

Women with PCOS-related hair loss often benefit from treatments that address the underlying androgen excess:

• Spironolactone (anti-androgen medication)
• Combined oral contraceptives with anti-androgenic progestins
• Metformin or GLP-1 agonists for insulin resistance (which drives androgen production)
• Topical minoxidil to directly stimulate follicle growth

Evidence-Based Treatments That Actually Work

The good news: there are multiple FDA-recognized and clinically validated options for women with hair loss.

Minoxidil (Rogaine for Women) is the only FDA-approved topical treatment for female pattern hair loss. The 2% solution is approved for women; many physicians also prescribe the 5% foam off-label, which has shown superior results in clinical studies. Minoxidil works by extending the anagen phase and increasing follicle size. It must be used consistently (once or twice daily) to maintain results — stopping minoxidil causes any regained hair to shed within 3–6 months.

Spironolactone is an oral anti-androgen widely prescribed off-label for female hair loss, particularly in women with FPHL, PCOS, or elevated androgens. It works by blocking androgen receptors at the hair follicle. Studies show meaningful improvement in hair density after 6–12 months of use. It requires a prescription and monitoring for blood pressure and potassium levels. It is contraindicated in pregnancy.

Low-Level Laser Therapy (LLLT): FDA-cleared devices (laser caps, combs) stimulate follicle activity via photobiomodulation. Evidence supports modest benefit for FPHL when used consistently.

Platelet-Rich Plasma (PRP): Injections of concentrated growth factors from your own blood are increasingly used for FPHL with growing evidence for efficacy — though typically reserved for in-clinic treatment rather than telehealth.

Lifestyle Factors and Nutritional Support

While lifestyle alone cannot reverse FPHL or androgenetic causes, optimizing these factors supports treatment outcomes and can address contributing causes like TE:

• Protein intake: Hair is primarily keratin. Inadequate dietary protein (less than 0.8 g/kg body weight) impairs hair growth.
• Iron and ferritin: Optimize ferritin above 40–70 ng/mL for optimal hair cycle function.
• Biotin: Only beneficial if you have a deficiency (rare in most people). Biotin supplementation in people without deficiency does not improve hair growth.
• Zinc and selenium: Deficiencies in either can drive TE; supplementation helps when labs confirm deficiency.
• Stress management: Chronic cortisol elevation disrupts the hair cycle. Sleep quality and stress reduction support hormonal balance.
• Gentle hair care: Avoid heat damage, tight styles, and over-processing, which worsen follicle stress.

How Truventa Medical Helps Women With Hair Loss

Women's hair loss is often dismissed or undertreated in conventional medicine. At Truventa Medical, our physicians specialize in identifying the root hormonal and clinical causes of female hair loss — not just prescribing a generic topical treatment and sending you home.

Our approach includes a thorough intake review, targeted lab work (hormones, thyroid, iron panel), and a personalized treatment plan that may include topical minoxidil, oral spironolactone, hormonal treatment, or a combination tailored to your specific pattern and labs. All consultations are done via telehealth, available in all 50 states, and you can message your care team anytime with questions about your progress.